DT2216 [196, 197], in particular, has entered preclinical research stages, demonstrating promising safety and selectivity in various Bcl‐xL‐dependent tumor models, providing new approaches for addressing Bcl‐xL “druggability challenges.” Here, BCL2L1 is linked to neoplasm.